Piper Jaffray analyst Matt O'Brien notes that Zimmer Biomet reported Q1 results that beat his top and bottom line targets, but manufacturing issues at its Biomet facility resulted in a modest guide down. The analyst believes this issue will be largely transitory and with a sticky hip/knee customer base, he doubts the effects will weigh on Zimmer Biomet for long. Further, he believes the company can return to improved top line results during the second half, and encourages patient investors to start building positions at these levels. The analyst reiterates an Overweight rating and $141 price target on the shares.